Top

Published in:

Open Access 01-10-2009 | Review Article

Migraine pain: reflections against vasodilatation

Authors: Alessandro Panconesi, Maria Letizia Bartolozzi, Leonello Guidi

Published in: The Journal of Headache and Pain | Issue 5/2009

Abstract

The original Wolff’s vascular theory of migraine was supported by the discovery of a class of drugs, the triptans, developed as a selective cephalic vasoconstrictor agents. Even in the neurovascular hypothesis of Moskowitz, that is the neurogenic inflammation of meningeal vessels provoked by peptides released from trigeminal sensory neurons, the vasodilatation provoked by calcitonin gene-related peptide (CGRP) is considered today much more important than oedema. The role of cephalic vasodilatation as a cause of migraine pain was recently sustained by studies showing the therapeutic effect of CGRP receptor antagonists. We discuss the evidence against vasodilatation as migraine pain generator and some findings which we suggest in support of a central (brain) origin of pain.

Moskowitz MA (2007) Pathophysiology of headache—past and present. Headache 27(Suppl 1):S58–S63. doi:10.1111/j.1526-4610.2007.00678.xCrossRef

Parsons AA, Strijbos PJ (2003) The neuronal versus vascular hypothesis of migraine and cortical spreading depression. Curr Opin Pharmacol 3:73–77. doi:10.1016/S1471-4892(02)00016-4CrossRefPubMed

Edvinsson L, Hamel E (2002) Perivascular nerves in brain vessels. In: Edvinsson L, Krause DN (eds) Cerebral blood flow and metabolism, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, pp 43–67

Edvinsson L, Uddman R (2005) Neurobiology in primary headaches. Brain Res Rev 48:438–456. doi:10.1016/j.brainresrev.2004.09.007CrossRefPubMed

Hargreaves R (2007) New migraine and pain research. Headache 47(Suppl 1):S26–S43. doi:10.1111/j.1526-4610.2006.00675.xCrossRefPubMed

Wolff HG (1963) Headache and other head pain. Oxford University Press, New York

Moskowitz MA (1984) The neurobiology of vascular head pain. Ann Neurol 16:157–186. doi:10.1002/ana.410160202CrossRefPubMed

Goadsby PJ, Edvinsson L, Ekman R (1988) Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol 23:193–196. doi:10.1002/ana.410230214CrossRefPubMed

Durham PL (2006) Calcitonin gene-related peptide (CGRP) and migraine. Headache 46(Suppl 1):S3–S8. doi:10.1111/j.1526-4610.2006.00483.xPubMedCentralCrossRefPubMed

10.

Humphrey PPA (2007) The discovery of a new drug class for the acute treatment of migraine. Headache 47(Suppl 1):S10–S19. doi:10.1111/j.1526-4610.2007.00672.xCrossRefPubMed

11.

Sicuteri F (1976) Hypothesis: migraine, a central biochemical dysnociception. Headache 16:145–159. doi:10.1111/j.1526-4610.1976.hed1604145.xCrossRefPubMed

12.

Sicuteri F, Del Bianco PL, Anselmi B (1979) Morphine abstinence and serotonin supersensitivity in man: analogies with the mechanism of migraine? Psychopharmacology 65:205–209. doi:10.1007/BF00433050CrossRefPubMed

13.

Sicuteri F (1987) Quasi-phantom head pain from functional deafferentation. Clin J Pain 3:63–80. doi:10.1097/00002508-198703020-00001CrossRef

14.

Sullivan JT, Preston KL, Testa MP, Busch M, Jasinski DR (1992) Psychoactivity and abuse potential of sumatriptan. Clin Pharmacol Ther 52:635–642CrossRefPubMed

15.

Panconesi A, Franchi G, Anselmi B, Curradi C (1994) On the mechanism of sumatriptan side effects. In: Fusco BM, Giacovazzo M (eds) Unilateral headache: focus on recent advances. RD Editori, Rome, pp 111–116

16.

Dodick DW, Martin V (2004) Triptans and CNS side-effects: pharmacokinetic and metabolic mechanism. Cephalalgia 24:417–424. doi:10.1111/j.1468-2982.2004.00694.xCrossRefPubMed

17.

Panconesi A, Sicuteri R (1997) Headache induced by serotonergic agonists–a key to the interpretation of migraine pathogenesis? Cephalalgia 17:3–14. doi:10.1046/j.1468-2982.1997.1701003.xCrossRefPubMed

18.

Panconesi A, Pavone E, Vacca F, Vaiani M, Banfi R (2008) Triptans in the Italian population: a drug utilization study and a literature review. J Headache Pain 9:71–76. doi:10.1007/s10194-008-0020-3PubMedCentralCrossRefPubMed

19.

Humphrey PPA (2008) The discovery and development of the triptans, a major therapeutic breakthrough. Headache 48:685–687. doi:10.1111/j.1526-4610.2008.01097.xCrossRefPubMed

20.

Moskowitz MA (1991) The visceral organ brain: implications for the pathophysiology of vascular head pain. Neurology 41:182–186CrossRefPubMed

21.

Geppetti P, Capone JG, Trevisani M, Nicoletti P, Zagli G, Tola MR (2005) CGRP and migraine: neurogenic inflammation revisited. J Headache Pain 6:61–70. doi:10.1007/s10194-005-0153-6PubMedCentralCrossRefPubMed

22.

Villalon CM, Centurion D (2007) Cardiovascular responses produced by 5-hydroxytryptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn-Schmiedeberg’s Arch Pharmacol 376:45–63. doi:10.1007/s00210-007-0179-1CrossRef

23.

Markowitz S, Saito K, Moskowitz MA (1988) Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 8:83–91. doi:10.1046/j.1468-2982.1988.0802083.xCrossRefPubMed

24.

Tfelt-Hansen PC, Koehler PJ (2008) History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 28:877–886. doi:10.1111/j.1468-2982.2008.01578.xCrossRefPubMed

25.

Shields KG, Goadsby PJ (2006) Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol Dis 23:491–501. doi:10.1016/j.nbd.2006.04.003CrossRefPubMed

26.

Jeong H-J, Chenu D, Johnson EE, Connor M, Vaughan CW (2008) Sumatriptan inhibits synaptic transmission in the rat midbrain periaqueductal grey. Mol Pain. doi:10.1186/1744-8069-4-54

27.

Levy D, Jakubowski M, Burstein R (2004) Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT_1B/1D receptor agonists. Proc Natl Acad Sci USA 101:4274–4279. doi:10.1073/pnas.0306147101PubMedCentralCrossRefPubMed

28.

Strassman AM, Levy D (2006) Response properties of dural nociceptors in relation to headache. J Neurophysiol 95:1298–1306. doi:10.1152/jn.01293.2005CrossRefPubMed

29.

Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI (2003) Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci 23:10988–10997PubMed

30.

Bartsch T, Knight YE, Goadsby PJ (2004) Activation of 5-HT_1B/1D receptor in the periaqueductal gray inhibits nociception. Ann Neurol 56:371–381. doi:10.1002/ana.20193CrossRefPubMed

31.

Nikai T, Basbaum AI, Ahn AH (2008) Profound reduction of somatic and visceral pain in mice by intrathecal administration of the anti-migraine drug, sumatriptan. Pain 139:533–540. doi:10.1016/j.pain.2008.06.002PubMedCentralCrossRefPubMed

32.

Carmichael NME, Charlton MP, Dostrovsky JO (2008) Activation of the 5-HT_1B/D receptor reduces hindlimb neurogenic inflammation caused by sensory nerve stimulation and capsaicin. Pain 134:97–105. doi:10.1016/j.pain.2007.03.037CrossRefPubMed

33.

Vera-Portocarrero LP, Ossipov MH, King T, Porreca F (2008) Reversal of inflammatory and noninflammatory visceral pain by central or peripheral actions of sumatriptan. Gastroenterology 135:1369–1378. doi:10.1053/j.gastro.2008.06.085PubMedCentralCrossRefPubMed

34.

Burstein R, Jakubowski M, Levy D (2005) Anti-migraine action of triptans is preceded by transient aggravation of headache caused by activation of meningeal nociceptors. Pain 115:21–28. doi:10.1016/j.pain.2005.01.027CrossRefPubMed

35.

Visser WH, de Vriend RH, Jaspers NH, Ferrari MD (1996) Sumatriptan–nonresponders: a survey in 366 migraine patients. Headache 36:471–475. doi:10.1046/j.1526-4610.1996.3608471.xCrossRefPubMed

36.

Panconesi A (2008) Serotonin and migraine: a reconsideration of the central theory. J Headache Pain 9:267–276. doi:10.1007/s10194-008-0058-2PubMedCentralCrossRefPubMed

37.

Ostfeld AM (1960) Migraine headache: its physiology and biochemistry. JAMA 174:1188–1190CrossRefPubMed

38.

Kimball RW, Friedman AP, Vallejo E (1960) Effect of serotonin in migraine patients. Neurology 10:107–111CrossRefPubMed

39.

Anthony M, Hinterberger H, Lance JW (1967) Plasma serotonin in migraine and stress. Arch Neurol 16:544–552CrossRefPubMed

40.

Tfelt-Hansen P (2007) Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine: a comment. J Headache Pain 8:273–276. doi:10.1007/s10194-007-0411-xPubMedCentralCrossRefPubMed

41.

Edvinsson L (2004) Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 24:611–622. doi:10.1111/j.1468-2982.2003.00719.xCrossRefPubMed

42.

Link AS, Kuris A, Edvinsson L (2008) Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 9:5–12. doi:10.1007/s10194-008-0011-4PubMedCentralCrossRefPubMed

43.

Goadsby PJ, Edvinsson L, Ekman R (1990) Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183–187. doi:10.1002/ana.410280213CrossRefPubMed

44.

Juhasz G, Zsombok T, Modos EA, Olajos S, Jakab B, Nemeth J, Szolcsanyi J, Vitrai J, Bagdy G (2003) NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106:461–470. doi:10.1016/j.pain.2003.09.008CrossRefPubMed

45.

Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22:54–61. doi:10.1046/j.1468-2982.2002.00310.xCrossRefPubMed

46.

Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM (2004) Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 350:1104–1110. doi:10.1056/NEJMoa030505CrossRefPubMed

47.

Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304–1312. doi:10.1212/01.WNL.0000286940.29755.61CrossRefPubMed

48.

Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J (2005) No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 58:561–568. doi:10.1002/ana.20605CrossRefPubMed

49.

Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J (2005) BIBN4096BS antagonizes human a-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 77:202–213. doi:10.1016/j.clpt.2004.10.001CrossRefPubMed

50.

Lassen LH, Jacobsen VB, Haderslev PA, Sperling B, Iversen HK, Olesen J, Tfelt-Hansen P (2008) Involvement of calcitonin gene-related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. J Headache Pain 9:151–157. doi:10.1007/s10194-008-0036-8PubMedCentralCrossRefPubMed

51.

Edvinsson ML, Edvinsson L (2008) Comparison of CGRP and NO responses in the human peripheral microcirculation of migraine and control subjects. Cephalalgia 28:563–566. doi:10.1111/j.1468-2982.2008.01558.xCrossRefPubMed

52.

de Hoon JN, Smits P, Troost J, Struijker-Boudier HA, Van Bortel LM (2006) Forearm vascular response to nitric oxide and calcitonin gene-related peptide: comparison between migraine patients and control subjects. Cephalalgia 26:56–63. doi:10.1111/j.1468-2982.2005.00993.xCrossRefPubMed

53.

Hansen JM, Thomsen LL, Olesen J, Ashina M (2008) Calcitonin gene related peptide does not cause the familial hemiplegic migraine phenotype. Neurology 71:841–847. doi:10.1212/01.wnl.0000325482.64106.3fCrossRefPubMed

54.

Schoonman GG, van der Grond J, Kortmann C, van der Geest RJ, Terwindt GM, Ferrari MD (2008) Migraine headache is not associated with cerebral or meningeal vasodilation—a 3T magnetic resonance angiography study. Brain 131:2192–2200. doi:10.1093/brain/awn094CrossRefPubMed

55.

Olesen J, Iversen HK, Thomsen LL (1993) Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. NeuroReport 4:1027–1030CrossRefPubMed

56.

Olesen J (2008) The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther 120:157–171. doi:10.1016/j.pharmthera.2008.08.003CrossRefPubMed

57.

Kruuse C, Thomsen LL, Jacobsen TB, Olesen J (2002) The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab 22:1124–1131. doi:10.1097/00004647-200209000-00010CrossRefPubMed

58.

Kruuse C, Thomsen LL, Birk S, Olesen J (2003) Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126:241–247. doi:10.1093/brain/awg009CrossRefPubMed

59.

Kruuse C, Lassen LH, Iversen HK, Oestergaard S, Olesen J (2006) Dipyridamole may induce migraine in patients with migraine without aura. Cephalalgia 26:925–933. doi:10.1111/j.1468-2982.2006.01137.xCrossRefPubMed

60.

Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J (2006) The headache-inducing effect of cilostazol in human volunteers. Cephalalgia 26:1304–1309. doi:10.1111/j.1468-2982.2006.01218.xCrossRefPubMed

61.

Birk S, Petersen KA, Kruuse C, Guieu R, Jonassen O, Eisert W, Olesen J (2005) The effect of circulating adenosine on cerebral haemodynamics and headache generation in healthy subjects. Cephalalgia 25:369–377. doi:10.1111/j.1468-2982.2005.00867.xCrossRefPubMed

62.

Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M (2008) Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28:226–236. doi:10.1111/j.1468-2982.2007.01497.xCrossRefPubMed

63.

Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132:16–25. doi:10.1093/brain/awn307CrossRefPubMed

64.

Schytz HW, Wienecke T, Oturai PS, Olesen J, Ashina M (2009) The cholinomimetic agent carbachol induces headache in healthy subjects. Cephalalgia 29:258–268. doi:10.1111/j.1468-2982.2008.01715.xCrossRefPubMed

65.

Petersen KA, Birk S, Kitamura K, Olesen J (2009) Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. Cephalalgia 29:23–30. doi:10.1111/j.1468-2982.2008.01695.xCrossRefPubMed

66.

Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J (2003) The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs. Cephalalgia 23:877–886. doi:10.1046/j.1468-2982.2003.00586.xCrossRefPubMed

67.

Burnstein R, Jakubowski M (2005) Unitary hypothesis for multiple triggers of the pain and strain of migraine. J Comp Neurol 493:9–14. doi:10.1002/cne.20688CrossRef

68.

Hansen JM, Petersen J, Wienecke T, Olsen KS, Jensen LT, Ashina M (2009) Sumatriptan does not change calcitonin gene-related peptide in the cephalic and extracephalic circulation in healthy volunteers. J Headache Pain 10:85–91. doi:10.1007/s10194-009-0102-xPubMedCentralCrossRefPubMed

69.

Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997) Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat–intravital microscope studies. Cephalalgia 17:525–531. doi:10.1046/j.1468-2982.1997.1704525.xCrossRefPubMed

70.

Munoz-Islas E, Gupta S, Jimenez-Mena LR, Lozano-Cuenca J, Sanchez-Lopez A, Centurion D, Mehrotra S, Maassen Van Den Brink A, Villalon CM (2006) Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT_1B rather 5-HT_1D receptors. Br J Pharmacol 149:82–91. doi:10.1038/sj.bjp.0706839PubMedCentralCrossRefPubMed

71.

Sheykhzade M, Nyborg NC (2004) Homologous desensitization of calcitonin gene-related peptide-induced relaxation in rat intramural coronary arteries. Eur J Pharmacol 484:91–101. doi:10.1016/j.ejphar.2003.10.052CrossRefPubMed

72.

Ebersberger A, Ringkamp M, Reeh PW, Handwerker HO (1997) Recording from brain stem neurons responding to chemical stimulation of subarachnoid space. J Neurophysiol 77:3122–3133PubMed

73.

Edvinsson L, Tfelt-Hansen P (2008) The blood-brain barrier in migraine treatment. Cephalalgia 28:1245–1258. doi:10.1111/j.1468-2982.2008.01675.xCrossRefPubMed

74.

Suzuki R, Rygh LJ, Dickenson AH (2004) Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 25:613–617. doi:10.1016/j.tips.2004.10.002CrossRefPubMed

75.

Mason P (2005) Deconstructing endogenous pain modulation. J Neurophysiol 94:1659–1663. doi:10.1152/jn.00249.2005CrossRefPubMed

76.

Benarroch EE (2008) Descending monoaminergic pain modulation: Bidirectional control and clinical relevance. Neurology 71:217–221. doi:10.1212/01.wnl.0000318225.51122.63CrossRefPubMed

77.

Carlson JD, Maire JJ, Martenson ME, Heinricher MM (2007) Sensitization of pain-modulating neurons in the rostral ventromedial medulla after peripheral nerve injury. J Neurosci 27:13222–13231. doi:10.1523/JNEUROSCI.3715-07.2007CrossRefPubMed

78.

Zhao Z-Q, Chiechio S, Sun Y-G, Zhang K-H, Zhao C-S, Scott M, Johnson RL, Deneris ES, Renner KJ, RW Gereau IV, Chen Z-F (2007) Mice lacking central serotonergic neurons show enhanced inflammatory pain and an impaired analgesic response to antidepressant drugs. J Neurosci 27:6045–6053. doi:10.1523/JNEUROSCI.1623-07.2007CrossRefPubMed

79.

Zhao Z-Q, Gao Y-J, Sun Y-G, Zhao C-S, Gereau RW IV, Chen Z-F (2007) Central serotonergic neurons are differentially required for opioid analgesia but not for morphine tolerance or morphine reward. Proc Natl Acad Sci USA 104:14519–14524. doi:10.1073/pnas.0705740104PubMedCentralCrossRefPubMed

80.

Moja PL, Cusi C, Sterzi RR, Canepari C (2007) Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headache (review). The Cochrane Library 4:1–50

81.

Sicuteri F, Boccuni M, Fanciullacci M, Gatto G (1983) Naloxone effectiveness on spontaneous and induced perceptive disorders in migraine. Headache 23:179–183. doi:10.1111/j.1526-4610.1983.hed2304179.xCrossRefPubMed

82.

Nicolodi M (1996) Differential sensitivity to morphine challenge in migraine sufferers and headache-exempt subjects. Cephalalgia 16:297–304. doi:10.1046/j.1468-2982.1996.1605297.xCrossRefPubMed

83.

Saper JR, Lake AE III (2008) Continuous opioid therapy (COT) is rarely advisable for refractory chronic daily headache: limited efficacy, risks, and proposed guidelines. Headache 48:838–849. doi:10.1111/j.1526-4610.2008.01153.xCrossRefPubMed

84.

Panconesi A, Anselmi B, Franchi G (1995) Increased adverse effects of opiates in migraine patients. Cephalalgia 15:159–160CrossRefPubMed

85.

Friedman BW, Kapoor A, Friedman MS, Hochberg ML, Rowe BH (2008) The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials. Ann Emerg Med 52:705–713. doi:10.1016/j.annemergmed.2008.05.036PubMedCentralCrossRefPubMed

86.

Ross JR, Riley J, Taegetmeyer AB, Sato H, Gretton S, du Bois RM, Welsh KI (2008) Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 112:1390–1403. doi:10.1002/cncr.23292CrossRefPubMed

87.

Coppola G, Pierelli F, Schoenen J (2008) Habituation and migraine. Neurobiol Learn Mem. doi:10.1016/j.nlm.2008.07.006

88.

Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC (1995) Brain stem activation in spontaneous human migraine attacks. Nat Med 1:658–660. doi:10.1038/nm0795-658CrossRefPubMed

89.

Bahra A, Matharu MS, Buchel C, Franckowiak RS, Goadsby PJ (2001) Brainstem activation specific to migraine headache. Lancet 357:1016–1017. doi:10.1016/S0140-6736(00)04250-1CrossRefPubMed

90.

Afridi SK, Giffin NJ, Kaube H, Friston KJ, Ward NS, Frackowiak RSJ, Goadsby PJ (2005) A positron enission tomographic study in spontaneous migraine. Arch Neurol 62:1270–1275. doi:10.1001/archneur.62.8.1270CrossRefPubMed

91.

Sakai Y, Dobson C, Diksic M, Aubè M, Hamel E (2008) Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology 70:431–439. doi:10.1212/01.wnl.0000299095.65331.6fCrossRefPubMed

92.

Lothe A, Merlet I, Demarquay G, Costes N, Ryvlin P, Mauguière F (2008) Interictal brain 5-HT_1A receptors binding in migraine without aura: a ¹⁸F-MPPF-PET study. Cephalalgia 28:1282–1291. doi:10.1111/j.1468-2982.2008.01677.xCrossRefPubMed

93.

De Tommaso M, Lo Sito L, Di Fruscolo O, Sardaro M, Prudenzano MP, Lamberti P, Livrea P (2005) Lack of habituation of nociceptive evoked responses and pain sensitivity during migraine attack. Clin Neurophysiol 116:1254–1264. doi:10.1016/j.clinph.2005.02.018CrossRefPubMed

94.

Bingel U, Schoell E, Herken W, Buchel C, May A (2007) Habituation to painful stimulation involves the antinociceptive system. Pain 131:21–30. doi:10.1016/j.pain.2006.12.005CrossRefPubMed

95.

Moulton EA, Burstein R, Tully S, Hargreaves R, Becerra L, Borsook D (2008) Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS ONE. doi:10.1371/journal.pone.0003799

96.

Brighina F, Palermo A, Fierro B (2009) Cortical inhibition and habituation to evoked potentials: relevance for pathophysiology of migraine. J Headache Pain 10:77–84. doi:10.1007/s10194-008-0095-xPubMedCentralCrossRefPubMed

97.

Goadsby PJ (2007) Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med 13:39–44. doi:10.1016/j.molmed.2006.11.005CrossRefPubMed

98.

Lambert GA, Hoskin KL, Zagami AS (2008) Cortico-NRM influences on trigeminal neuronal sensation. Cephalalgia 28:640–652. doi:10.1111/j.1468-2982.2008.01572.xCrossRefPubMed

99.

Dodick DW (2008) Examining the essence of migraine–Is it the blood vessel or the brain? A debate. Headache 48:661–667CrossRefPubMed

100.

Rothrock JF (2008) “Outside-In” vs “Inside-Out”: revisiting migraine’s vascular hypothesis. Headache 48:1409–1410. doi:10.1111/j.1526-4610.2008.01276.xCrossRefPubMed

101.

Cutrer FM, Charles A (2008) The neurogenic basis of migraine. Headache 48:1411–1414. doi:10.1111/j.1526-4610.2008.01277.xCrossRefPubMed

102.

Dahl E, Edvinsson L (1988) Anatomical organization of cerebral and extracerebral vasculature. In: Olesen J, Edvinsson L (eds) Basic mechanisms of headache. Elsevier, Amsterdam, pp 27–47

Title: Migraine pain: reflections against vasodilatation
Authors: Alessandro Panconesi
Maria Letizia Bartolozzi
Leonello Guidi
Publication date: 01-10-2009
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 5/2009
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1007/s10194-009-0130-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Migraine pain: reflections against vasodilatation

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

Psychometric properties of the Danish versions of Headache-Specific Locus of Control Scale and Headache Management Self-Efficacy Scale

What can be learned from the history of recurrence in migraine? A comment

Headache, cardiac arrest, and intracranial hemorrhage

Trigger factors in childhood migraine: a clinic-based study from Eastern India

Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism

Who’s still afraid of the link between headache and epilepsy? Some reactions to and reflections on the article by Marte Helene Bjørk and co-workers